Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01897116 · ClinicalTrials.gov registry record · Phase 1
A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01897116 is a Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 8 participants.
The verdict
NCT01897116, a Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a Phase I study combining vemurafenib and hydroxychloroquine in the treatment of BRAF V600E+ metastatic melanoma.
Interventions
- DRUG Hydroxychloroquine (HCQ)
- DRUG Vemurafenib (VEM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-06 |
| Est. Completion | 2016-10-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01897116
The ClinicalTrials.gov registry entry for NCT01897116 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Hydroxychloroquine (HCQ) is the first listed.
NCT01897116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01897116 about?
NCT01897116 is a clinical study titled "A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma". This is a Phase I study combining vemurafenib and hydroxychloroquine in the treatment of BRAF V600E+ metastatic melanoma.
What is the current status of trial NCT01897116?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2013-06. Estimated completion is 2016-10-05.
What interventions are being tested in trial NCT01897116?
The interventions under investigation include: Hydroxychloroquine (HCQ) (DRUG), Vemurafenib (VEM) (DRUG).
Who is sponsoring clinical trial NCT01897116?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.